Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
- PMID: 16254181
- DOI: 10.1126/science.1117679
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
Abstract
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1, were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5' untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1. Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
Comment in
-
Medicine. Fused genes may help explain the origins of prostate cancer.Science. 2005 Oct 28;310(5748):603. doi: 10.1126/science.310.5748.603a. Science. 2005. PMID: 16254158 No abstract available.
-
Re: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.Eur Urol. 2007 May;51(5):1443-4. doi: 10.1016/j.eururo.2007.02.021. Eur Urol. 2007. PMID: 17494120 No abstract available.
Similar articles
-
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.Mod Pathol. 2007 Sep;20(9):921-8. doi: 10.1038/modpathol.3800903. Epub 2007 Jul 13. Mod Pathol. 2007. PMID: 17632455
-
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.Cancer Res. 2006 Nov 15;66(22):10658-63. doi: 10.1158/0008-5472.CAN-06-1871. Cancer Res. 2006. PMID: 17108102
-
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.Cancer Res. 2008 May 15;68(10):3584-90. doi: 10.1158/0008-5472.CAN-07-6154. Cancer Res. 2008. PMID: 18483239 Free PMC article.
-
[The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].Yi Chuan. 2011 Feb;33(2):117-22. doi: 10.3724/sp.j.1005.2011.00117. Yi Chuan. 2011. PMID: 21377967 Review. Chinese.
-
[TMPRSS2-ETS gene fusion in prostate cancer].Urologe A. 2007 Jul;46(7):754-60. doi: 10.1007/s00120-007-1347-0. Urologe A. 2007. PMID: 17458530 Review. German.
Cited by
-
Exploration of PVT1 as a biomarker in prostate cancer.Medicine (Baltimore). 2024 Aug 23;103(34):e39406. doi: 10.1097/MD.0000000000039406. Medicine (Baltimore). 2024. PMID: 39183420 Free PMC article.
-
Oncogenic SLC2A11-MIF fusion protein interacts with polypyrimidine tract binding protein 1 to facilitate bladder cancer proliferation and metastasis by regulating mRNA stability.MedComm (2020). 2024 Aug 14;5(9):e685. doi: 10.1002/mco2.685. eCollection 2024 Sep. MedComm (2020). 2024. PMID: 39156764 Free PMC article.
-
Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer.Nat Commun. 2024 Aug 6;15(1):6672. doi: 10.1038/s41467-024-50908-7. Nat Commun. 2024. PMID: 39107274 Free PMC article.
-
Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms.Front Mol Med. 2023 Jan 4;2:1035290. doi: 10.3389/fmmed.2022.1035290. eCollection 2022. Front Mol Med. 2023. PMID: 39086962 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials